The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Acute Bacterial Skin And Skin Structure Infections Market During The Forecast Period?
The market for acute bacterial skin and skin structure infections has experienced robust growth in recent years. This market is projected to expand from $12.9 billion in 2025 to $14.09 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Historically, this expansion has been driven by factors such as the restricted availability of broad-spectrum antibiotics, an increase in hospital-acquired infections, greater awareness regarding complications from skin infections, improved access to community healthcare, and the implementation of standard infection control protocols.
The market size for acute bacterial skin and skin structure infections is expected to undergo rapid expansion over the next few years, projected to reach $20.79 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This growth during the forecast period is attributed to factors such as the development of next-generation antibiotics, increasing investments in antimicrobial research, the expansion of community-based infection management programs, the broadening of hospital pharmacy distribution channels, and the implementation of rapid diagnostic technologies. Major trends anticipated in this period include a rising incidence of acute bacterial skin and skin structure infections, the growing adoption of novel antibiotics and combination therapies, the expansion of hospital and community healthcare facilities, an increasing use of oral and parenteral antibiotics, and a concentrated focus on reducing hospital-acquired infection rates.
Access Your Free Sample Report For In-Depth Market Analysis:
What Significant Factors Are Influencing The Acute Bacterial Skin And Skin Structure Infections Market Expansion?
The increasing occurrence of skin infections is projected to fuel the expansion of the acute bacterial skin and skin structure infections market in the future. These infections refer to conditions where microorganisms like bacteria, fungi, or viruses penetrate and proliferate within the skin, causing diverse symptoms and unease. An uptick in skin infections generates a heightened need for therapeutic remedies, antibiotics, and novel treatments to manage acute bacterial and skin structure infections, thus ensuring optimal patient care and results. To illustrate, data from March 2023 by the World Health Organization, a Switzerland-based specialized agency of the United Nations, indicated that approximately 1.8 billion individuals worldwide are simultaneously affected by skin conditions. Neglected tropical diseases (NTDs) account for roughly 10% of these cases, while fungal infections constitute 34% and bacterial infections 23%, frequently resulting in elevated mortality rates. Consequently, the growing occurrence of skin infections is set to stimulate the expansion of the acute bacterial skin and skin structure infections market.
What Segment Categories Shape The Acute Bacterial Skin And Skin Structure Infections Market Segment Landscape?
The acute bacterial skin and skin structure infections market covered in this report is segmented –
1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections
What Trends Are Affecting The Direction Of The Acute Bacterial Skin And Skin Structure Infections Market?
Leading companies within the acute bacterial skin and skin structure infections market are prioritizing the development of innovative single-dose therapies, such as Dalbonova, to secure a competitive advantage. Dalbonova represents a single-dose treatment delivering both convenience and efficacy, allowing patients to achieve desired outcomes with a potent 1500 mg dose administered only once. For example, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company focused on API and formulation therapeutic segments, including acute bacterial skin and skin structure infections, launched Dalbonova injection, a single-dose therapy specifically for acute bacterial skin and skin structure infections (ABSSSI). This Dalbonova Injection lessens the risk of hospital-acquired illnesses by providing a single-dose regimen and removing the requirement for hospital admissions. It is formulated to treat acute bacterial skin and skin structure infections (ABSSSI) stemming from particular gram-positive microorganisms in patients across all age categories, including newborns.
Who Are The Companies Operating Across The Acute Bacterial Skin And Skin Structure Infections Market Value Chain?
Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group
Get The Full Acute Bacterial Skin And Skin Structure Infections Market Report:
Which Region Dominates The Acute Bacterial Skin And Skin Structure Infections Market By Market Share?
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Acute Bacterial Skin And Skin Structure Infections Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Acute Bacterial Skin And Skin Structure Infections Market 2026, By The Business Research Company
Dermatitis Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Complicated Skin And Skin Structure Infections Drugs Market Report 2026
Antimicrobial Medical Device Coatings Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model